IPP Bureau
Novartis AG wins case against four domestic pharma firms
By IPP Bureau - November 03, 2021
The injunction order has been passed against Natco Pharma, Torrent Pharmaceuticals, Eris Lifesciences and Windlas Biotech
U.S. FDA approves ANI’s purified cortrophin gel
By IPP Bureau - November 03, 2021
Cortrophin gel is purified corticotropin (ACTH), an important treatment option for patients struggling with certain chronic autoimmune disorders. It acquired the NDA for cortrophin gel from Merck & Co. in 2016
Lonza to acquire Exosomics service unit in Italy
By IPP Bureau - November 03, 2021
Expertise in exosomes isolation and characterization will drive innovation in this field
Lancet endorses Sputnik Light for safety and immune response
By IPP Bureau - November 03, 2021
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
Covaxin shelf-life extended to 12 months from the date of manufacture
By IPP Bureau - November 03, 2021
This approval of shelf-life extension was based on the availability of additional stability data, which was submitted to CDSCO
WHO issues emergency use listing for Covaxin
By IPP Bureau - November 03, 2021
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
Novavax and Serum Institute receive EUA for Covid-19 vaccine in Indonesia
By IPP Bureau - November 02, 2021
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
Thermo Fisher Scientific realigns product portfolio
By IPP Bureau - November 02, 2021
Consolidation of the Acros Organics, Alfa Aesar and Maybridge brands to one single brand, Thermo Scientific
AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma
By IPP Bureau - November 02, 2021
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
Built-for-purpose offering for biomolecule attribute monitoring
By IPP Bureau - November 02, 2021
The Thermo Scientific Orbitrap Exploris MX enables customer success by combining high-quality data with operational simplicity
SOPHiA Genetics launches SOPHiA DDM to assist Agilent customers
By IPP Bureau - November 02, 2021
New bioinformatic workflow advances analysis capabilities for whole-exome assessment and interpretation
Caplin Point Labs posts Q2FY22 PAT at Rs 74.98 Cr
By IPP Bureau - November 02, 2021
The Board of Directors of Caplin Point Laboratories at its meeting have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
Lyka Labs Q2FY22 consolidated PAT at Rs. 28.43Cr
By IPP Bureau - November 01, 2021
Lyka Labs has reported consolidated financial results for the period ended September 30, 2021
GlaxoSmithKline posts Q2FY22 consolidated PAT at Rs. 204.24 Cr
By IPP Bureau - November 01, 2021
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
Dr Reddys Laboratories posts Q2FY22 PAT at Rs 992 Cr
By IPP Bureau - November 01, 2021
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended September 30, 2021
